Sertindole

Cat. No.: HY-14543
CAS No.: 106516-24-9
Molecular Formula: $C_{24}H_{26}ClFN_4O$
Molecular Weight: 440.94
Target: 5-HT Receptor; Dopamine Receptor; Adrenergic Receptor; Autophagy
Pathway: GPCR/G Protein; Neuronal Signaling; Autophagy
Storage:
- Powder: -20°C 3 years
- 4°C 2 years
- In solvent: -80°C 6 months
- -20°C 1 month

SOLVENT & SOLUBILITY

In Vitro
DMSO: 25 mg/mL (56.70 mM; Need ultrasonic)

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Solvent Mass</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solvent Concentration</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 mM</td>
<td>2.2679 mL</td>
<td>11.3394 mL</td>
<td>22.6788 mL</td>
<td></td>
</tr>
<tr>
<td>5 mM</td>
<td>0.4536 mL</td>
<td>2.2679 mL</td>
<td>4.5358 mL</td>
<td></td>
</tr>
<tr>
<td>10 mM</td>
<td>0.2268 mL</td>
<td>1.1339 mL</td>
<td>2.2679 mL</td>
<td></td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

In Vivo
1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (5.67 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (5.67 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (5.67 mM); Clear solution

BIOLOGICAL ACTIVITY

Description
Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Target: Multi-target
In vitro studies showed that sertindole exerts a potent antagonism at serotonin 5-HT2A, 5-HT2C, dopamine D2, and α1 adrenergic receptors. Sertindole offers an alternative treatment option for refractory patients given its good EPS profile, favorable metabolic profile, and comparable efficacy to risperidone. Due to cardiovascular safety concerns, sertindole is available as a second-line choice for patients intolerant to other antipsychotic agents [1]. Sertindole should prove to be a very useful addition to the therapeutic options available for the treatment of psychotic disorders [2].
Sertindole improves negative symptoms, and is also effective for the treatment of neuroleptic-resistant schizophrenia. Sertindole is generally well tolerated and is associated with a low rate of extrapyramidal symptoms (EPS). Thus, sertindole is a useful option in the treatment of patients with schizophrenia [3].

| IC₅₀ & Target | 5-HT₂A Receptor | 5-HT₂C Receptor |

REFERENCES

